2022
DOI: 10.55544/jrasb.1.2.2
|View full text |Cite
|
Sign up to set email alerts
|

Plant & Its Derivative Shows Therapeutic Activity on Neuroprotective Effect

Abstract: In most cases, the death of neurons in certain parts of the brain is the defining feature of a condition that is classified as neurodegenerative. There have been studies conducted on both conventional and innovative drugs, however the results have shown that they only offer symptomatic advantages and come with a number of undesirable side effects. The finding of more potent compounds that can stop the pathophysiology of these diseases will be seen as a miracle in the present day. There is a wide variety of syn… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 0 publications
0
13
0
Order By: Relevance
“…Originating in China, this plant is now widely cultivated in India for its decorative value. Flavonoids, anthocyanins, quercetin, cyanidin, kaempferol, and hydrocitric acid are all found inside this plant [45].…”
Section: Hibiscus Rosa-sinensismentioning
confidence: 95%
See 3 more Smart Citations
“…Originating in China, this plant is now widely cultivated in India for its decorative value. Flavonoids, anthocyanins, quercetin, cyanidin, kaempferol, and hydrocitric acid are all found inside this plant [45].…”
Section: Hibiscus Rosa-sinensismentioning
confidence: 95%
“…You can find it in its natural habitat in the Western Hemisphere and the sub-Himalayas, as well as in India, Pakistan, Asia Minor, Africa, and Arabia. Alkaloids, flavonoids, saponin, tannins, zeatin, quercetin, kaempferom, and terpenoids are all present in this plant [45].…”
Section: Moringa Oleiferamentioning
confidence: 96%
See 2 more Smart Citations
“…On the other hand, the predictive biomarker is often integrated into the designs of clinical trials at a late stage in the clinical review process. For instance, in phase II research of combinations with DNA-damaging cytotoxics [64], it may be more acceptable to choose patients based on an epigenomic subtype of DDR genes as opposed to a histological subtype.…”
Section: Challenges and Future Prospectivesmentioning
confidence: 99%